YanaPikmanMD

Pediatric Hematology & Oncology • Boston, MA

Clinical Fellow in Pediatrics, Boston Children's Hospital

Join to view full profile

Dr. Pikman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pikman's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3701

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2010 - 2013
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2007 - 2010
Harvard Medical SchoolClass of 2007

Certifications & Licensure

MA State Medical License 2010 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome Start of enrollment: 2016 Aug 17
Active, not recruiting
Not Applicable

Publications & Presentations

PubMed

1082 citations
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Yana Pikman, Benjamin H. Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L. Ebert
Plos Medicine. 2006-07-18
5 citations
Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress.
Brian T Do, Peggy P Hsu, Sidney Y Vermeulen, Zhishan Wang, Taghreed Hirz
Developmental Cell. 2024-08-19
8 citations
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Wallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, Daniela V Wenge, Florian Perner
Blood. 2024-04-11

Journal Articles

Targeted Therapy for Fusion-Driven High-Risk Acute Leukemia
Kimberly Stegmaier, Yana Pikman, Blood

Abstracts/Posters

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies
Yana Pikman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Leukemia Research Foundation Awards $1.3 Million in GrantsAugust 28th, 2020